Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AGIOS PHARMACEUTICALS, INC.

(AGIO)
  Report
Delayed Nasdaq  -  04:00 2022-12-08 pm EST
28.69 USD   +2.72%
12/07Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-07-2022 11:25 AM
CI
12/06Agios Pharmaceuticals, Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
12/06Agios Appoints Tsveta Milanova as Chief Commercial Officer
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2022 12/05/2022 12/06/2022 12/07/2022 12/08/2022 Date
31.52(c) 29.8(c) 28.6(c) 27.93(c) 28.69 Last
460 555 620 790 428 482 380 174 343 801 Volume
+7.25% -5.46% -4.03% -2.34% +2.72% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 13,5 M - -
Net income 2022 -341 M - -
Net cash position 2022 198 M - -
P/E ratio 2022 -4,55x
Yield 2022 -
Sales 2023 31,3 M - -
Net income 2023 -372 M - -
Net cash position 2023 161 M - -
P/E ratio 2023 -4,28x
Yield 2023 -
Capitalization 1 576 M 1 576 M -
EV / Sales 2022 102x
EV / Sales 2023 45,2x
Nbr of Employees 391
Free-Float 76,2%
More Financials
Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 11:25amPresentation
More about the company
Ratings of Agios Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
B-
More Ratings
All news about AGIOS PHARMACEUTICALS, INC.
12/07Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America 2022 Vir..
CI
12/06Agios Pharmaceuticals, Inc. : Change in Directors or Principal Officers, Financial Stateme..
AQ
12/06Agios Appoints Tsveta Milanova as Chief Commercial Officer
AQ
12/06Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effec..
CI
12/01JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains..
MT
11/30Agios to Participate in December Investor Conference
AQ
11/18North American Morning Briefing: Stocks to Edge -2-
DJ
11/17Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral from Sell, Lifts Price Target t..
MT
11/11Agios Pharmaceuticals, Inc. - PYRUKYND Approved in the EU for the Treatment of Pyruvate..
AQ
11/10PYRUKYND« (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Defi..
AQ
11/10Agios Pharmaceutical's PYRUKYND« Approves in the EU for the Treatment of Pyruvate Kinas..
CI
11/04RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform R..
MT
11/03AGIOS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/03Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/03Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chroni..
AQ
More news
News in other languages on AGIOS PHARMACEUTICALS, INC.
12/06Agios Pharmaceuticals, Inc. nomme Tsveta Milanova au poste de directeur commercial, à c..
11/10PYRUKYND« d'Agios Pharmaceutical est approuvé dans l'UE pour le traitement de la défici..
11/03Agios Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les ne..
10/27Agios Pharmaceuticals, Inc. et Sagard Healthcare Partners annoncent un accord d'achat d..
09/16Agios Pharmaceuticals, Inc. Reçoit un avis positif de la Chmp pour Pyrukynd« (Mitapivat..
More news
Analyst Recommendations on AGIOS PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on AGIOS PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
First Trust NYSE Arca Biotechnology Index F...3.16%-1.02%United_States
First Trust NYSE Arca Biotechnology - Acc - USD3%1.18%-United_States
Virtus LifeSci Biotech Products ETF - USD2.53%-0.80%United_States
ALPS Medical Breakthroughs ETF - USD0.75%-4.81%United_States
SPDR S&P Biotech ETF - USD0.62%0.76%United_States
More ETFs positioned on AGIOS PHARMACEUTICALS, INC.
Chart AGIOS PHARMACEUTICALS, INC.
Duration : Period :
Agios Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGIOS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 28,69 $
Average target price 36,20 $
Spread / Average Target 26,2%
EPS Revisions
Managers and Directors
Brian M. Goff Chief Executive Officer & Director
Cecilia Jones Chief Financial Officer
Jacqualyn A. Fouse Chairman
Clive Patience Executive Vice President-Technical Operations
Sarah Gheuens Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AGIOS PHARMACEUTICALS, INC.-15.03%1 535
REGENERON PHARMACEUTICALS, INC.18.36%81 626
VERTEX PHARMACEUTICALS41.99%81 520
BIONTECH SE-36.92%39 522
WUXI APPTEC CO., LTD.-32.50%32 802
GENMAB A/S23.27%29 855